Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson oncology Therapeutic Area Total — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
7,602
Period ended Sep 30, 2026
Change on a year earlier
+16.4%
6,529 in Q3 2025
History
40 quarters
Since Q4 2016
Sources
32
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Oncology Therapeutic Area Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 7,602 | +16.4% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 7,406 | +17.3% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 6,973 | +22.8% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 6,861 | +24.8% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 6,529 | +21.4% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 6,312 | +24.0% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 5,678 | +17.9% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 5,497 | +19.0% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 5,380 | +18.7% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 5,090 | +15.7% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,814 | +17.1% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 4,618 | +17.6% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2023 | Oct 1, 2023 | 4,533 | +11.5% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 4,398 | +8.8% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 4,112 | +4.1% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 3,927 | +3.9% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 4,064 | +10.9% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 4,042 | +14.3% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 3,950 | +10.6% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 3,778 | +10.0% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 3,665 | +17.1% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 3,535 | +26.7% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 3,570 | +18.5% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 3,434 | +26.4% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 3,129 | +13.3% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 2,791 | +3.5% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 3,013 | +19.7% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 2,716 | +9.1% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 2,761 | +6.7% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,697 | +9.8% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 2,518 | +9.0% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 2,489 | +22.1% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 2,588 | +36.4% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 2,456 | +42.2% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 2,311 | +45.0% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 2,039 | +39.5% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 1,898 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 1,727 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 1,594 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2016 | Jan 1, 2017 | 1,462 | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up oncology therapeutic area total — worldwide sales ($m)
- Oncology Therapeutic Area Total — U.S. sales ($M)4,267 · Q3 2026
- Oncology Therapeutic Area Total — International sales ($M)3,335 · Q3 2026
- Oncology Therapeutic Area Total — Worldwide reported growth YoY (%)16.4% · Q3 2026
- Oncology Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)16.7% · Q3 2026
- DARZALEX (daratumumab) — Worldwide sales ($M)4,239 · Q3 2026
- ERLEADA (apalutamide) — Worldwide sales ($M)1,023 · Q3 2026
- CARVYKTI (ciltacabtagene autoleucel) — Worldwide sales ($M)710 · Q3 2026
- IMBRUVICA (ibrutinib) — Worldwide sales ($M)563 · Q3 2026
- RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide sales ($M)320 · Q3 2026
- TECVAYLI (teclistamab) — Worldwide sales ($M)312 · Q3 2026
- TALVEY (talquetamab) — Worldwide sales ($M)171 · Q3 2026
- ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide sales ($M)119 · Q4 2025
- VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide sales ($M)97 · Q4 2020
- Other Oncology medicines — Worldwide sales ($M)262 · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson Oncology Therapeutic Area Total — Worldwide sales ($M) ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta_oncology
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.